Nurix (NASDAQ: NRIX) CFO awarded 93,750 options and 42,875 RSUs

Q: What equity awards did Nurix (NRIX) CFO Hans van Houte receive on February 10, 2026?

Nurix CFO Hans van Houte received a stock option for 93,750 shares at $16.45 per share and 42,875 RSUs . The option and RSUs vest over three years, rewarding continued service with potential future share ownership.

Q: How do the new stock options for Nurix (NRIX) CFO vest over time?

The 93,750-share stock option vests as to 1/36 of the total shares each month starting March 10, 2026 . Vesting continues monthly until February 9, 2029 , conditioned on Hans van Houte continuing to provide services to Nurix.

Q: What is the vesting schedule for the 42,875 RSUs granted to Nurix (NRIX) CFO?

The 42,875 RSUs vest 1/12 of the total award quarterly over three years, with the first vesting date on July 30, 2026 . Shares of common stock are delivered after each vesting date if the CFO is still serving Nurix.

Q: Are the new Nurix (NRIX) CFO equity awards held directly or indirectly?

The filing shows both the 93,750 stock options and 42,875 RSUs as held with direct ownership by the reporting person. No related entities, trusts, or partnerships are indicated in the ownership or footnotes for these specific awards.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Nurix Therapeutics Chief Financial Officer Hans van Houte received new equity awards in the form of stock options and restricted stock units. On February 10, 2026, he was granted an employee stock option for 93,750 shares of common stock at an exercise price of $16.45 per share, vesting in equal monthly installments over three years until February 9, 2029, while he continues serving the company.

He was also granted 42,875 restricted stock units, each representing one share of common stock. These RSUs vest in equal quarterly installments over three years, with the first portion vesting on July 30, 2026, contingent on his continued service; vested shares will be delivered after each vesting date.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider van Houte Hans

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	93,750	$0.00	$0.00
Grant/Award	Restricted Stock Units	42,875	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 93,750 shares (Direct); Restricted Stock Units — 42,875 shares (Direct)

Footnotes (4)

F1. The stock option vests as to 1/36 of the total shares monthly beginning March 10, 2026, until the option is fully vested on February 9, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F3. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
F4. RSUs do not expire; they either vest or are canceled prior to the vest date.

FAQ

What equity awards did Nurix (NRIX) CFO Hans van Houte receive on February 10, 2026?

Nurix CFO Hans van Houte received a stock option for 93,750 shares at $16.45 per share and 42,875 RSUs. The option and RSUs vest over three years, rewarding continued service with potential future share ownership.

How do the new stock options for Nurix (NRIX) CFO vest over time?

The 93,750-share stock option vests as to 1/36 of the total shares each month starting March 10, 2026. Vesting continues monthly until February 9, 2029, conditioned on Hans van Houte continuing to provide services to Nurix.

What is the vesting schedule for the 42,875 RSUs granted to Nurix (NRIX) CFO?

The 42,875 RSUs vest 1/12 of the total award quarterly over three years, with the first vesting date on July 30, 2026. Shares of common stock are delivered after each vesting date if the CFO is still serving Nurix.

What does each RSU granted to Nurix (NRIX) CFO represent?

Each RSU granted to the CFO represents a contingent right to receive one share of Nurix common stock. RSUs either vest on the specified schedule or are canceled before vesting, and do not have a traditional expiration date like options.

What is the exercise price of the Nurix (NRIX) CFO’s new stock option award?

The employee stock option granted to the CFO has an exercise price of $16.45 per share of Nurix common stock. He may choose to exercise vested portions of the option at this price, subject to the continued service and vesting conditions.

Are the new Nurix (NRIX) CFO equity awards held directly or indirectly?

The filing shows both the 93,750 stock options and 42,875 RSUs as held with direct ownership by the reporting person. No related entities, trusts, or partnerships are indicated in the ownership or footnotes for these specific awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/10/2026 - 06:09 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

van Houte Hans

(Last)

(First)

(Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE

94005

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$16.45	02/10/2026		A		93,750		⁽¹⁾	02/09/2036	Common Stock	93,750	$0	93,750	D
Restricted Stock Units	$0⁽²⁾	02/10/2026		A		42,875		⁽³⁾	⁽⁴⁾	Common Stock	42,875	$0	42,875	D

Explanation of Responses:

1. The stock option vests as to 1/36 of the total shares monthly beginning March 10, 2026, until the option is fully vested on February 9, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

3. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

4. RSUs do not expire; they either vest or are canceled prior to the vest date.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Hans van Houte	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR